Results 281 to 290 of about 820,835 (359)

Gene List Selection Matters: Missed Diagnoses in Prenatal Exome Sequencing—PanelApp R21 and HPO‐Driven Versus OMIM‐Based Gene Lists

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Objective To evaluate whether the causative variants found upon clinical exome sequencing in fetuses affected with selected structural anomalies would also be detected if PanelApp‐R21 or Human Phenotype Ontology (HPO)‐driven gene selection terms were applied instead.
Victoria Ardiles‐Ruesjas   +7 more
wiley   +1 more source

Sex Ratios at Birth Following Non‐Invasive Prenatal Testing in Victoria, Australia

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Objective Non‐invasive prenatal testing (NIPT) can determine fetal chromosomal sex early in pregnancy, raising the possibility of sex selection. However, current evidence regarding this practice is limited. Our objective was to assess the sex ratio at birth (SRB) among a cohort of infants born following NIPT from a single laboratory provider ...
Hilary Bowman‐Smart   +6 more
wiley   +1 more source

Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta-analysis. [PDF]

open access: yesActa Obstet Gynecol Scand
Zhao Y   +6 more
europepmc   +1 more source

Recurrent miscarriage and low-titer antiphospholipid antibodies. [PDF]

open access: yesClin Rheumatol
Chen J   +5 more
europepmc   +1 more source

Predicting Pharmacological Treatment Response in Migraine Using AI/ML: A Scoping Review of the Evidence and Future Directions

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT The treatment of migraine is hampered by inter‐individual variability, leading to an inefficient “trial and error” approach. Artificial intelligence (AI) and machine learning (ML) offer a path towards precision medicine by predicting therapeutic outcomes.
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Home - About - Disclaimer - Privacy